Wed, Jul 23, 2014, 5:19 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

BIOLASE, Inc. Message Board

  • brennamae brennamae Feb 20, 2004 12:19 AM Flag

    secondary next wednesday?

    look under current offerings.com
    Needham news

    Good luck all longs

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • but they can always blame it on the writer if they need a way out!!!Which in BLTI case they will not have to use because it will be way over a 50% increase.

    • brennamae post

      Now, with regard to secondary stock offerings, the firm�s been a constant on the offering gauntlet. Next week is no exception. Needham has two deals on the launching pad: Biolase Technology (BLTI) and Vasogen (VSGN). For the year, it has already completed two other follow-on deals and has had banking positions in other deals. Those lead secondary transactions included a Feb. 9 pricing for KVH Industries (KVHI) and Intevac (IVAC), a deal priced on Feb. 4. SG Cowen Securities was a co-lead manager on the KVH Industries transaction.

      Biolase Technology has set next Wednesday for pricing of its pending secondary offering. Terms: 2.8 million shares [filed at $20.13], of which the company is selling 2.5 million. Needham is the lead banker. William Blair and Oppenheimer & Co. are acting as co-managers. The company bills itself as the world�s largest dental laser company, having sold over 2,000 laser systems in more than 20 countries. Strength for the lasers is based upon approvals by government regulators in the United States, Canada and European Union to market such lasers.

      A bonus: the firm posted full-year profitability of $1.5 million in 2002. Upbeat guidance, with the predication that 2003�s figures will be higher than its previously stated goal of 40%-50% sales growth, issued by the company on Feb. 4 has helped propel shares in market trading in anticipation of its 2003 earnings release set for Mar. 3 . The stock, recently quoted at $20.35, trades in the upper boundary of its 52-week range.

      http://www.currentofferings.com/ipostory.cfm?recordID=129

      • 3 Replies to ehwest2
      • "A bonus: the firm posted full-year profitability of $1.5 million in 2002. Upbeat guidance, with the predication that 2003�s figures will be higher than its previously stated goal of 40%-50% sales growth, issued by the company on Feb. 4 has helped propel shares in market trading in anticipation of its 2003 earnings release set for Mar. 3"

        FROM ABOVE!!!
        "predication that 2003�s figures will be higher than its previously stated goal of 40%-50% sales growth"

        <<<<<<<BY DEDUCTION that reads {higher then the "40%-50% sales goal} >>>>>

        This is the underwriters literature and is directed towards their institutional accounts, and AT THE ROAD SHOW it's probably what BLTI gives as an answer to any question pertaining to 2003 earnings.

        Or to put it another way: Imagine this scenario. An institutional account buys BLTI stock at the secondary offering a few days later earnings come out and they are 50% above 2003 earnings, the stock takes a hit. Many institutions start calling Mr. Big at Needham to tell him that

        ("higher then "40%-50%")does not mean 50% and that they are professionals and want to be treated as such or else.

        Needham would suffer a loss of GOODWILL that is very important to their underwriting business. Professionals don't like sales hyperbole it demeans them.

        SUMMARY: I'd would bet my life it's going to be substantially over 50%.

      • Like I said last week I'll bet Needham/Oppenheimer and Biolase have got a dollar figure for the offering already set too.

    • Biolase Technology has set next Wednesday for pricing of its pending secondary offering. Terms: 2.8 million shares [filed at $20.13], of which the company is selling 2.5 million. Needham is the lead banker. William Blair and Oppenheimer & Co. are acting as co-managers. The company bills itself as the world�s largest dental laser company, having sold over 2,000 laser systems in more than 20 countries. Strength for the lasers is based upon approvals by government regulators in the United States, Canada and European Union to market such lasers.

    • link, please?

 
BIOL
2.18+0.06(+2.83%)Jul 23 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.